Biopharmaceutical company Chiasma has updated the terms of its Nasdaq IPO with the US Securities and Exchange Commission (SEC). The company, which recently submitted a request for marketing approval of its drug for treatment of acromegaly, a diseas stemming from excessive hormone growth, will raise $80 million, and up to $92 million if the underwriters options are realized. Barclays Capital and Cowen & Co. are leading the offering with William Blair and Oppenheimer as the secondary underwriters… READ MORE
Published by Globes [online], Israel business news – www.globes-online.com
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Chiasma Raises $70 Million to Advance Its Endocrine Disease Medication
Israeli-American privately held biomed company Chiasma announced the closing of a $70 million Series E financing round. The company will use the new capital to build its sales and marketing capabilities and prepare More…
Israeli-American Biomed Firm Chiasma Raises $33.8 Million to Continue Development of Oral Meds
Israeli biomed company Chiasma has raised $33.8 million out of a planned total $56.3 million round of fundraising. It plans to use the infusion of new capital to continue the development of its oral octreotide. MPM More…
Roche Cancels $600 Million Chiasma Deal
Chiasma: The product is good. This was a strategic decision by Roche to be less involved in hormone-based drugs. – Roche AG (SWX: ROG) has notified Israeli startup Chiasma that it has cancelled a commercial More…